Search results for "Clero"

showing 10 items of 2052 documents

Incremento dei livelli di 17-idrossiprogesterone in pazienti con sclerosi multipla in età pediatrica

2009

Settore MED/38 - Pediatria Generale E Specialisticasclerosi multipla 17-idrossiprogesterone
researchProduct

Sleep–wake problems in patients with amyotrophic lateral sclerosis: implications for patient management. NEURODEGENERATIVE DISEASE MANAGEMENT

2012

SUMMARY Sleep–wake problems are frequent, although unrecognized, complications of amyotrophic lateral sclerosis (ALS). Sleep disorders such as insomnia, sleep-disordered breathing and restless legs syndrome have all been reported in patients with ALS, despite the limited number of studies and the small populations investigated so far. Sleep disturbances gradually worsen with disease progression, suggesting a relationship between the severity of disease and the neurodegenerative process. However, poor sleep can also be a consequence of several disturbances such as anxiety, depression, pain, choking, sialorrhea, fasciculations, cramps, nocturia and the inability to get comfortable and move fr…

Settore MED/44 - Medicina Del LavoroSettore MED/26 - Neurologiasleepamyotrophic lateral sclerosis patient management
researchProduct

Botulinum Toxin Is Effective in the Management of Neurogenic Dysphagia. Clinical-Electrophysiological Findings and Tips on Safety in Different Neurol…

2017

Background and Aims: Neurogenic dysphagia linked to failed relaxation of the upper esophageal sphincter (UES) can be treated by injecting botulinum toxin (BTX) into the cricopharyngeal (CP) muscle. We compared the effects of this treatment in different neurological disorders with dysphagia, to evaluate its efficacy over time including the response to a second injection. Materials and Methods: Sixty-seven patients with neurogenic dysphagia associated with incomplete or absent opening of the UES (24 with brainstem or hemispheric stroke, 21 with parkinsonian syndromes, 12 with multiple sclerosis, and 10 with spastic-dystonic syndromes secondary to post-traumatic encephalopathy) were treated wi…

Side effectEncephalopathyupper esophageal sphincter dysmotilityneurogenic dysphagia03 medical and health sciences0302 clinical medicineSwallowingmedicineIngestionPharmacology (medical)botulinum toxinOriginal ResearchPharmacologybusiness.industryelectrophysiological study of swallowingMultiple sclerosiscricopharyngeal musclemedicine.diseaseDysphagiaBotulinum toxinPneumoniaAnesthesia030211 gastroenterology & hepatologymedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugFrontiers in Pharmacology
researchProduct

The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multipl…

2020

The IL22RA2 locus is associated with risk for multiple sclerosis (MS) but causative variants are yet to be determined. In a single nucleotide polymorphism (SNP) screen of this locus in a Basque population, rs28385692, a rare coding variant substituting Leu for Pro at position 16 emerged significantly (p = 0.02). This variant is located in the signal peptide (SP) shared by the three secreted protein isoforms produced by IL22RA2 (IL-22 binding protein-1(IL-22BPi1), IL-22BPi2 and IL-22BPi3). Genotyping was extended to a Europe-wide case-control dataset and yielded high significance in the full dataset (p = 3.17 &times

Signal peptideGene isoformSignal peptidePopulationSingle-nucleotide polymorphismLocus (genetics)610 Medicine & healthBiologymultiple sclerosisMultiple sclerosis03 medical and health sciences0302 clinical medicineSNPIL-22 binding protein isoformsignal peptideddc:610Alleleeducation610 Medicine &amp; healthlcsh:QH301-705.5Peptide sequence030304 developmental biology0303 health scienceseducation.field_of_studyautoimmuneGeneral MedicineMolecular biologylcsh:Biology (General)<i>IL22RA2</i>IL22RA2Mutation[SDV.IMM]Life Sciences [q-bio]/Immunologymutation030217 neurology & neurosurgeryAutoimmune
researchProduct

Apposition of silica lamellae during growth of spicules in the demosponge Suberites domuncula: Biological/biochemical studies and chemical/biomimetic…

2006

Recently it has been discovered that the formation of the siliceous spicules of Demospongiae proceeds enzymatically (via silicatein) and occurs matrix guided (on galectin strings). In addition, it could be demonstrated that silicatein, if immobilized onto inorganic surfaces, provides the template for the synthesis of biosilica. In order to understand the formation of spicules in the intact organism, detailed studies with primmorphs from Suberites domuncula have been performed. The demosponge spicules are formed from several silica lamellae which are concentrically arranged around the axial canal, harboring the axial filament composed of silicatein. Now we show that the appositional growth o…

Silicon dioxideNanotechnologyCatalysischemistry.chemical_compoundDemospongeSponge spiculeBiomimeticsStructural BiologyAnimalsSclerocyteNanotubesPropylaminesbiologyVesicleSilanesEnzymes ImmobilizedSilicon Dioxidebiology.organism_classificationCathepsinsSuberites domunculaLamella (surface anatomy)chemistryMicroscopy Electron ScanningBiophysicsSuberitesSuberitesJournal of Structural Biology
researchProduct

The clinical relevance of low-density-lipoproteins size modulation by statins.

2006

The predominance of small, dense low density lipoproteins (LDL) has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III; in fact, LDL size seems to be an important predictor of cardiovascular events and progression of coronary heart disease. Several studies have also shown that the therapeutical modulation of LDL size is of great benefit in reducing the risk of cardiovascular events. Hypolipidemic treatment is able to alter LDL subclass distribution and statins are currently the most widely used lipid-lowering agents. Statins are potent inhibitors of hydroxy-methyl-glutaryl-coenzyme A reductase, the rate-limiting en…

Simvastatinmedicine.medical_specialtyIndolesStatinmedicine.drug_classAtorvastatinFatty Acids MonounsaturatedInternal medicineAtorvastatinmedicineHumansPyrrolesPharmacology (medical)RosuvastatinParticle SizeRosuvastatin CalciumFluvastatinNational Cholesterol Education ProgramPharmacologySulfonamidesVascular diseasebusiness.industryAnticholesteremic Agentsstatins small dense LDL coronary heart disease atherosclerosis prevention therapyGeneral Medicinemedicine.diseaseFluorobenzenesLipoproteins LDLPyrimidinesEndocrinologyCardiovascular DiseasesHeptanoic AcidsSimvastatinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessPravastatinmedicine.drugFluvastatin
researchProduct

Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.

2023

Background and ObjectivesRelapsing-remitting multiple sclerosis (RRMS), aquaporin-4 antibody–positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) may have overlapping clinical features. There is an unmet need for imaging markers that differentiate between them when serologic testing is unavailable or ambiguous. We assessed whether imaging characteristics typical of MS discriminate RRMS from AQP4-NMOSD and MOGAD, alone and in combination.MethodsAdult, nonacute patients with RRMS, APQ4-NMOSD, and MOGAD and healthy controls were prospectively recruited at the National Hospital for Neurology and Neurosurgery (L…

Sistema nerviós central - MalaltiesMalalties autoimmunitàries:aminoácidos péptidos y proteínas::proteínas::glicoproteínas::glicoproteínas de membranas::butirofilinas::glicoproteína mielínica del oligodendrocito [COMPUESTOS QUÍMICOS Y DROGAS]:Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Myelitis Transverse::Neuromyelitis Optica [DISEASES]:enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::mielitis transversa::neuromielitis óptica [ENFERMEDADES]:Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Multiple Sclerosis [DISEASES]Esclerosi múltiple:Amino Acids Peptides and Proteins::Proteins::Glycoproteins::Membrane Glycoproteins::Butyrophilins::Myelin-Oligodendrocyte Glycoprotein [CHEMICALS AND DRUGS]:Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]:enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES]Imatgeria per ressonància magnèticaNA:diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Neurology (clinical)Neurology
researchProduct

Restless legs syndrome in patients with amyotrophic lateral sclerosis

2010

We aimed to evaluate the frequency and determinants of restless legs syndrome (RLS) in a group of 76 patients with amyotrophic lateral sclerosis (ALS) and 100 control subjects. A diagnosis of RLS was made according to the criteria of the International RLS Study Group, and severity was assessed by the RLS severity scale. RLS was significantly more frequent in patients with ALS (ALS/RLS(+)) than in control subjects (25% vs. 8%; P = 0.002). Compared with control subjects, patients with ALS/RLS(+) showed shorter history of RLS complaints and higher frequency of symptoms occurrence. Moreover, compared with those without RLS, patients with ALS/RLS(+) showed increased functional impairment and mor…

Sleep disordermedicine.medical_specialtyOdds ratioNeurological disordermedicine.diseaseComorbidityCentral nervous system diseaseNeurologyInternal medicinemental disordersSeverity of illnessmedicinePhysical therapyNeurology (clinical)Restless legs syndromeAmyotrophic lateral sclerosisPsychologyMovement Disorders
researchProduct

Low-density-lipoproteins size and cardiovascular prevention

2005

Low-density lipoprotein (LDL) size appears to be an important predictor of cardiovascular events and progression of coronary artery disease, and the predominance of small, dense LDL has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. Yet, other authors have suggested that LDL subclass measurement does not add independent information to that conferred generically by LDL concentration and other standard risk factors. Therefore, the debate continues as to whether to measure LDL particle size for cardiovascular prevention and, if so, in which categories of patients. Since the therapeutic modulation of distinct LDL …

Small dense ldlmedicine.medical_specialtyFramingham Risk Scorebusiness.industryPreventionSmall dense LDLmedicine.diseaseCoronary artery diseaseCoronary heart diseasechemistry.chemical_compoundchemistryCardiovascular preventionRisk factorsLow-density lipoproteinInternal medicineAtherosclerosiInternal MedicinemedicineCardiologylipids (amino acids peptides and proteins)Risk factorbusinessNational Cholesterol Education ProgramLipoprotein
researchProduct

Small, dense low-density lipoproteins are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome.

2008

Small dense low-density lipoproteins cardiovascular events the metabolic syndrome.aterosclerosi
researchProduct